Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

Lawsuit is part of a nationwide strategy by Novo Nordisk to protect its trademark and profits from its blockbuster GLP-1 ...

Nearly 4.4 million adult New Yorkers, or 30%, have obesity, but access to weight-loss medications varies based on a variety ...

Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE ...

Medicare may cover Wegovy for adults with cardiovascular disease and either obesity or overweight. Learn more about Medicare ...

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...

Doctors are sending out a warning after children as young as 10 years old are using drugs like Ozempic and Wegovy.

The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors think ...

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...